Our Strategy

Our Strategy

Our Strategy

In order to exploit its high potential for innovation and growth, Ci3 is pursuing a five-point strategy:

  1. We are focusing on product sectors, specifically on targeted and effective immunotherapies with few side effects protected by patents and based on biomarkers in indications in which there is both a high unmet medical need and broad market potential (i.e. oncology, autoimmune and infectious diseases).
  2. We are fostering unbroken product development paths characterized by regional co-operations. These range from the identification of targets to research into mechanisms as well as to the development and manufacturing of lead substances, all the way to preclinical and clinical testing, and finally to marketing approval and commercialization. We intend to do all of this while creating collaborations among partners based on their respective strengths.
  3. We are securing excellent technical and management personnel over the long-term through appropriate incentives for top performers and through multidisciplinary training programs of academic institutions and industry.
  4. We are building a sustainable, results-oriented model for value creation, funding and growth with concerted efforts at innovation across all sectors of the health care industry.
  5. We are strengthening the cluster through the regular involvement of experts and key opinion leaders from academia, business, government, educational institutions, regulatory authorities and the health care sector.